Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
Type:
Grant
Filed:
May 13, 2016
Date of Patent:
March 5, 2019
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Brian Wong, Emma Masteller, Kris Reedquist
Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
January 8, 2019
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
Type:
Application
Filed:
June 8, 2018
Publication date:
January 3, 2019
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.
Type:
Application
Filed:
January 3, 2018
Publication date:
October 4, 2018
Applicants:
Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No. 2) Limited
Inventors:
Julie Hambleton, Maureen Bleam, Maurice P. DeYoung, Geraldine Ferron-Brady, Rakesh Kumar, Lone Ottesen
Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Type:
Grant
Filed:
December 21, 2015
Date of Patent:
August 7, 2018
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Robert Sikorski, Julie Hambleton, Nilacantan Sankar
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
Type:
Grant
Filed:
November 13, 2012
Date of Patent:
July 10, 2018
Assignee:
FIVE PRIME THERAPEUTICS, INC.
Inventors:
Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Type:
Application
Filed:
August 18, 2017
Publication date:
April 5, 2018
Applicants:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
Type:
Application
Filed:
April 12, 2016
Publication date:
March 29, 2018
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Emma Masteller, Thomas Brennan, David Bellovin, Kevin Baker, Brian Wong
Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
Type:
Application
Filed:
June 12, 2017
Publication date:
December 7, 2017
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin G.P. Wong, Ge Wu, Hongbing Zhang
Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
Type:
Grant
Filed:
May 22, 2014
Date of Patent:
October 3, 2017
Assignees:
Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No.2) Limited
Inventors:
David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Type:
Grant
Filed:
October 28, 2015
Date of Patent:
September 19, 2017
Assignees:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Type:
Application
Filed:
November 1, 2016
Publication date:
May 25, 2017
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
Type:
Application
Filed:
November 22, 2016
Publication date:
May 25, 2017
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides. This application also provides methods of predicting response to treatment of cancer, such as bladder or gastric cancer, with FGFR2 inhibitors by determining FGFR2 overexpression and/or gene amplification in tumor cells of cancer subjects before treatment with FGFR2 inhibitors either alone or in combination with immune stimulating agents.
Type:
Application
Filed:
November 22, 2016
Publication date:
May 25, 2017
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.